AZD4635: Phase I started

Sosei’s Heptares Therapeutics Ltd. subsidiary said AstraZeneca began an open-label, dose-escalation, U.S. Phase I trial to evaluate twice-daily oral HTL1071 alone and in combination with IV durvaluma...